Online citations, reference lists, and bibliographies.

Treatment Of Endogenous Fungal Endophthalmitis: Focus On New Antifungal Agents.

James Riddell, Grant M. Comer, Carol A. Kauffman
Published 2011 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Endogenous fungal endophthalmitis, involving only the chorioretinal structures or extending to involve the vitreous (vitritis), is a sight-threatening infection requiring early appropriate therapy. Endophthalmitis is a relatively frequent complication of candidemia and less commonly occurs in patients who have invasive aspergillosis. Because the eye is a protected compartment, penetration of systemically administered antifungal agents is highly variable. In the posterior segment of the eye, amphotericin B (AmB) achieves very poor concentrations, but fluconazole concentrations are high. Among newer antifungal agents, voriconazole shows the most promise, because therapeutic concentrations for most Candida and Aspergillus species are achieved in the vitreous, and its antifungal activity is broad. In contrast, neither posaconazole nor the 3 echinocandins achieve adequate therapeutic concentrations in the vitreous. For sight-threatening macular involvement and vitritis, intravitreal injection of either AmB or voriconazole is helpful to achieve high local antifungal activity as quickly as possible. We review the available evidence regarding the most appropriate use of antifungal agents for endogenous fungal endophthalmitis, with the emphasis on treatment of infections due to Candida species.
This paper references
10.1111/j.1469-0691.1997.tb00269.x
Intravenous penetration of fluconazole during endophthalmitis.
Michel Tod (1997)
10.1086/525258
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.
Thomas Walsh (2008)
update by the Infectious Diseases Society of America
TJ Walsh
10.1128/AAC.39.4.958
Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole.
Sukyung Park (1995)
10.1016/0002-9394(74)90012-9
Intravitreal amphotericin B toxicity.
E N Souri (1974)
Intravitreous penetration of fluconazole during endophthalmitis.
Michel Tod (1997)
10.1086/596757
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Peter G. Pappas (2009)
10.1016/0002-9394(73)90753-8
Toxicity of intravitreal injection of amphotericin B.
Alan J. Axelrod (1973)
10.1128/AAC.46.6.1857-1869.2002
Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits
Vidmantas Petraitis (2002)
10.1086/431761
Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.
Gregory M Gauthier (2005)
10.1086/524669
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
A. Delgado Pascual (2008)
10.1001/archopht.122.1.42
Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.
Seenu M Hariprasad (2004)
10.1016/S0734-3299(08)70531-8
Anidulafungin versus Fluconazole for Invasive Candidiasis
A. Kumar (2008)
iconazole in the treatment of fungal eye infections : a review of current literature
SM Hariprasad (2008)
10.1128/AAC.46.12.3719-3723.2002
Ocular Distribution of Intravenously Administered Lipid Formulations of Amphotericin B in a Rabbit Model
David Goldblum (2002)
10.1097/00005792-200207000-00007
Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature.
James C. Riddell (2002)
10.1007/s10633-005-7342-0
Retinal Function Assessed by ERG Before and After Induction of Ocular Aspergillosis and Treatment by the Anti-fungal, Micafungin, in Rabbits
Joseph M. Harrison (2005)
Intraocular distribution of intravitreally administered amphotericin B in normal and vitrectomized eyes.
Lemuel B. Wingard (1989)
10.1128/AAC.00674-08
Cerebrospinal Fluid and Plasma (1→3)-β-d-Glucan as Surrogate Markers for Detection and Monitoring of Therapeutic Response in Experimental Hematogenous Candida Meningoencephalitis
Ruta Petraitiene (2008)
10.1093/clinids/20.3.657
Use of fluconazole in the treatment of candidal endophthalmitis.
M E Akler (1995)
10.1093/infdis/147.1.164
Penetration of amphotericin B into the human eye.
John Fremont Fisher (1983)
10.1016/S0734-3299(08)70530-6
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
A Akshaya Kumar (2008)
10.1128/AAC.45.12.3322-3327.2001
Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits
Andreas H Groll (2001)
10.1128/AAC.33.4.467
Pharmacokinetics and tissue penetration of fluconazole in rabbits.
T J Walsh (1989)
10.1086/598933
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
Robert Betts (2009)
10.1016/j.ajo.2006.10.048
Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592).
Elmer Yuchen Tu (2007)
10.1159/000310473
Fluconazole in the management of fungal ocular infections.
Steen Fiil Urbak (1994)
10.1128/AAC.35.2.288
Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits.
Scott G. Filler (1991)
10.1016/S0161-6420(90)32547-2
Endogenous Candida endophthalmitis. Management without intravenous amphotericin B.
Roy D. Brod (1990)
10.1086/514972
Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy.
César Martínez-Vázquez (1998)
10.1128/AAC.50.4.1570-1572.2006
Voriconazole Therapeutic Drug Monitoring
J. E. Smith (2006)
Endogenous Aspergillus endophthalmitis . Rev Infect Dis
P Roney (1986)
10.1093/clinids/8.6.955
Endogenous aspergillus endophthalmitis.
P. Roney (1986)
10.3341/kjo.2005.19.1.73
Treatment of candida chorioretinitis with voriconazole.
Gyu Jin Jang (2005)
10.3928/1542-8877-19970301-03
Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis.
T F Essman (1997)
10.1001/archopht.122.11.1687
Intravitreal voriconazole: an electroretinographic and histopathologic study.
Hua Gao (2004)
10.1136/bjo.86.7.829
Do climatic variables influence the development of posterior vitreous detachment?
Rubina Rahman (2002)
Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits.
Carole Tremblay (1985)
10.1016/0002-9394(85)90791-3
Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys.
Michael Barza (1985)
10.1038/sj.eye.6701427
Use of voriconazole in candida retinitis
D. Prasanth Varma (2005)
COMPARISON OF CASPOFUNGIN AND AMPHOTERICIN B FOR INVASIVE CANDIDIASIS
OLEMAN (2002)
10.1086/520980
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Peter George Pappas (2007)
10.3109/02713688508999978
Intraocular penetration of systemically administered antifungal agents.
Denis M. O'day (1985)
10.1016/0002-9394(75)90628-5
Endogenous Aspergillus endophthalmitis occurring after kidney transplant.
Michael A. Naidoff (1975)
10.1007/s00417-006-0460-x
Ocular penetration of caspofungin in a rabbit uveitis model
David Goldblum (2006)
Aspergillus endophthalmitis in an intravenous drug user.
S S Wilmarth (1983)
10.1016/S1201-9712(02)90284-5
Endogenous Aspergillus Endophthalmitis: Report of 3 Cases and Review of the Literature
James Riddell (2002)
10.1136/bjo.86.7.829-a
Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis
William Eric Sponsel (2002)
10.1093/clind/15.6.910
Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review.
Josep Romeu i Bisbe (1992)
10.1136/bjo.2007.136515
Voriconazole in the treatment of fungal eye infections: a review of current literature
Seenu M Hariprasad (2008)
Ocular penetration of 5-fluorocytosine.
Arthur Donald Walsh (1978)
10.1086/427753
Candida glabrata endophthalmitis treated successfully with caspofungin.
Juan Carlos Sarria (2005)
10.1097/IAE.0b013e31818d4b9b
INTRAVITREAL VORICONAZOLE: In Vitro Safety-Profile for Fungal Endophthalmitis
Marcus Kernt (2009)
10.1128/AAC.43.12.2831
Efficacies of High-Dose Fluconazole plus Amphotericin B and High-Dose Fluconazole plus 5-Fluorocytosine versus Amphotericin B, Fluconazole, and 5-Fluorocytosine Monotherapies in Treatment of Experimental Endocarditis, Endophthalmitis, and Pyelonephritis Due to Candida albicans
Arnold Louie (1999)
10.1128/AAC.45.10.2845-2855.2001
Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling
Andreas H Groll (2001)
10.1016/S0161-6420(98)71225-3
Endogenous Aspergillus endophthalmitis. Clinical features and treatment outcomes.
P D Weishaar (1998)
10.1016/j.ajo.2004.08.077
Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.
Sean M. Breit (2005)
10.1093/clinids/17.5.888
Failure of therapy with fluconazole for candidal endophthalmitis.
Joji Nomura (1993)
10.1001/archopht.1965.00970030771004
OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS.
William R Green (1965)
10.1128/AAC.45.2.596-600.2001
Compartmental Pharmacokinetics of the Antifungal Echinocandin Caspofungin (MK-0991) in Rabbits
Andreas H Groll (2001)
10.1128/AAC.31.1.6
Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis.
D V Savani (1987)
10.1007/BF01643753
Candida endophthalmitis: Clinical presentation, treatment and outcome in 23 patients
Stephan Schmid (1991)
10.1167/iovs.02-1020
Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
Joan P. Cannon (2003)
10.1056/NEJM197203302861301
Hematogenous Candida endophthalmitis--a complication of candidemia.
L. S. Fishman (1972)
10.1167/iovs.06-1362
Clearance of intravitreal voriconazole.
Ying-Cheng Shen (2007)
10.1016/j.ophtha.2006.01.059
Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis.
Michal Kramer (2006)
10.1001/archopht.1990.01070090108050
Ocular uptake of fluconazole following oral administration.
Denis M. O'day (1990)
10.1097/00006982-200509000-00010
TREATMENT OUTCOMES AFTER PARS PLANA VITRECTOMY FOR ENDOGENOUS ENDOPHTHALMITIS
Yan-qiong Zhang (2005)
Clinical practice guidelines for the management of candidiasis :
PG Pappas (2009)



This paper is referenced by
OPTH_A_219264 2573..2582
Leopoldo Spadea (2019)
10.7599/HMR.2016.36.3.192
Ocular Inflammation Associated with Systemic Infection
Byung Gil Moon (2016)
10.1007/s00347-013-2797-y
[Iris tumor of unknown origin].
J. Rueping (2013)
10.1016/j.annemergmed.2011.07.033
Man with blurred vision. Endogenous candida endophthalmitis caused by urinary tract infection.
Kuan-Jen Chen (2012)
10.3201/eid1806.111765
Coccidioidal Endophthalmitis in Immunocompetent Person, California, USA
Michael L. Cheng (2012)
10.1002/9781118321492.ch11
11. Invasive Candidosis
Fsb FRCPath Malcolm D. Richardson PhD (2012)
10.1016/j.ajoc.2019.100475
Pseudozyma aphidis endophthalmitis post-cataract operation: Case discussion and management
Shong Min Voon (2019)
ARCHIVOS DE LA SOCIEDAD ESPAÑOLA DE OFTALMOLOGÍA
Enrique Santos-Bueso (2016)
10.1111/myc.12697
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia
Ilaria Rizzello (2018)
Performance Dependent Parameters of a Liposome Formulation of a Hydrophobic Drug
Xinpei Li (2018)
Antifungal Pharmacokinetics and Pharmacodynamics Subject Collection Human Fungal Pathogens Pneumocystis
Wright. (2014)
10.1016/j.ophtha.2014.06.042
Outcomes, impact on management, and costs of fungal eye disease consults in a tertiary care setting.
Devon H. Ghodasra (2014)
10.1016/j.oftal.2013.12.009
[Bilateral endogenous ophthalmitis due to Candida glabrata after complicated bariatric surgery].
O. Pizango (2014)
10.1111/imj.12598
Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Christopher C. Blyth (2014)
10.1016/B978-0-323-40181-4.00294-2
294 – Topical Antimicrobial Agents
Jane M. Gould (2012)
10.1016/J.OFTALE.2014.08.008
Bilateral endogenous ophthalmitis due to Candida glabrata after complicated bariatric surgery
O. Pizango (2014)
10.1186/s13104-018-3682-1
Sub-retinal abscess as presenting feature of endogenous Candida endophthalmitis
Sidra Zafar (2018)
10.1016/j.riam.2013.05.006
Épico Project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients.
Rafael Zaragoza (2013)
10.1016/J.JDDST.2016.08.009
Safety and in vivo release of fluconazole-loaded implants in rabbits' eyes
Gisele Rodrigues da Silva (2016)
Development of educational recommendations using the DELPHI echnique on invasive candidiasis in non-neutropenic critically ill adult patients
afael Zaragozaa (2018)
10.23937/2572-4045.1510047
Candida Retinitis in a Liver Transplantation Recipient
Aydan A. Kose (2020)
Review Optimizing antifungal choice and administration
David R Andes (2013)
10.1111/1469-0691.12039
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
O A Cornely (2012)
10.1007/s15010-018-1163-z
Prevalence of, and risk factors for, hematogenous fungal endophthalmitis in patients with Candida bloodstream infection
Hideaki Kato (2018)
10.1111/myc.12224
The role of surgical debridement in different clinical manifestations of invasive aspergillosis.
Frederike M J Reischies (2014)
10.5799/AHINJS.02.2011.02.0018
Successful salvage treatment of Lecythophora mutabilis keratitis with topical voriconazole
Orcun Pehlivan (2011)
10.1007/978-3-030-01751-4_63-1
Ophthalmic Infections in Transplant
Jacob E. Lemieux (2020)
10.1155/2015/249419
Infected Baerveldt Glaucoma Drainage Device by Aspergillus niger
Nurul-Laila Salim (2015)
10.1016/j.redar.2013.05.016
ÉPICO project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients.
Rafael Zaragoza (2013)
10.1007/s10384-015-0397-x
Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis
Jeong Hun Bae (2015)
10.1016/j.idc.2015.10.012
Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.
Jeniel E Nett (2016)
10.1007/s00347-017-0439-5
[Candida infiltrations in the iris and lens during iritis and situation after sepsis].
David Kuerten (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar